PhoenixBio Co., Ltd.

6190

JP3803010002

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 11:21:08 17/05/2024 am IST			5-day change	1st Jan Change
490 ^JPY	-6.49%		-0.81%	+5.15%

2023	PhoenixBio Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
2022	PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.	CI

Certain warrants of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.

September 13, 2016

Certain shares of PhoenixBio Co., Ltd.'s Warrants are subject to a Lock-Up Agreement Ending on 13-SEP-2016. These shares will be under lockup for 180 days starting from 17-MAR-2016 to 13-SEP-2016.

Latest news about PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	15/23/15	CI
PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.	13/22/13	CI
Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology Offering	06/21/06	CI
PhoenixBio Co., Ltd. announced that it has received ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor	30/20/30	CI
PhoenixBio Co., Ltd. announced that it expects to receive ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor	13/20/13	CI
PhoenixBio Co., Ltd. completed the acquisition of KMT Hepatech Inc. from a group of shareholders.	01/17/01	CI
PhoenixBio Co., Ltd. agreed to acquire KMT Hepatech Inc. from a group of shareholders for CAD 5.5 million.	14/17/14	CI
Certain shares of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.	13/16/13	CI
Certain warrants of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.	13/16/13	CI
PhoenixBio Co., Ltd. has completed an IPO in the amount of ¥984.00 million.	17/16/17	CI
PhoenixBio Co., Ltd. has filed an IPO.	15/16/15	CI

PhoenixBio Co., Ltd. is a Japan-based company mainly engaged in provision of contract research services of drug development, which uses PXB mouse. The PXB Mouse segment is engaged in the development of technology to create PXB Mouse in which more than 70% of mouse livers are replaced with human hepatocytes. The product called PXB Mouse is used in the preclinical process of the discovery of drugs.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PHOENIXBIO CO., LTD.	+5.15%	1.36Cr
MODERNA, INC.	+33.37%	5.08TCr
IQVIA HOLDINGS INC.	+1.55%	4.28TCr
LONZA GROUP AG	+49.11%	4.2TCr
CELLTRION, INC.	-4.22%	2.95TCr
ICON PUBLIC LIMITED COMPANY	+11.57%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	1.91TCr
BIO-TECHNE CORPORATION	+7.36%	1.31TCr
MEDPACE HOLDINGS, INC.	+28.30%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+23.80%	1.21TCr

Other Biotechnology & Medical Research

PhoenixBio Co., Ltd.

Equities

6190

JP3803010002

Biotechnology & Medical Research

Certain warrants of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.

Latest news about PhoenixBio Co., Ltd.

Chart PhoenixBio Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research